| Overview |
| bs-12430R |
| DAAM2 Polyclonal Antibody |
| ELISA, IHC-P, IHC-F, IF(IHC-P), IF(IHC-F), IF(ICC), ICC |
| Human |
| Mouse, Rat, Dog, Cow, Sheep, Pig, Horse, Rabbit |
| Specifications |
| Unconjugated |
| Rabbit |
| KLH conjugated synthetic peptide derived from human DAAM2 |
| 161-260/1068 |
| Polyclonal |
| IgG |
| 1ug/ul |
| Purified by Protein A. |
| 0.01M TBS(pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol. |
| Shipped at 4°C. Store at -20°C for one year. Avoid repeated freeze/thaw cycles. |
| Target |
| 23500 |
| Extracellular matrix |
| DAAM2; DAAM2_HUMAN; Disheveled-associated activator of morphogenesis 2; dishevelled associated activator of morphogenesis 2; dJ90A20A.1; KIAA0381; MGC90515; RP1 278E11.1. |
| DAAM2 is a widely expressed 1,068 amino acid protein that contains one DAD domain, one FH1 domain, one FH2 domain and one GBD domain, through which it may play a role in Wnt/Frizzled-associated signaling events. The gene encoding DAAM2 maps to human chromosome 6, which contains 170 million base pairs and comprises nearly 6% of the human genome. Deletion of a portion of the q arm of chromosome 6 is associated with early onset intestinal cancer, suggesting the presence of a cancer susceptibility locus. Additionally, Porphyria cutanea tarda, Parkinson's disease, Stickler syndrome and a susceptibility to bipolar disorder are all associated with genes that map to chromosome 6. |
| Application Dilution |
| ELISA |
1:500-1000 |
| IHC-P |
1:200-400 |
| IHC-F |
1:100-500 |
| IF(IHC-P) |
1:50-200 |
| IF(IHC-F) |
1:50-200 |
| IF(ICC) |
1:50-200 |
| ICC |
1:100-500 |
Powered by Bioz